HUMIRA® blir den første og eneste selvinjiserte biologiske behandlingsformen for moderat til alvorlig aktiv UC hos voksne.

HUMIRA® Becomes First and Only Self-injectable Biologic Therapy for the Treatment of Moderately to Severely Active UC in Adults.

Company Remains on Track for Separation into Two Publicly Traded Global Health Care Companies by End of 2012 ABBOTT PARK, Ill., March 21, 2012 – Abbott today announced that AbbVie [pronounced Abb-vee] will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012.